Venture Funding Deals: Spin-Outs From Axovant, Inovio & Sosei

 
• By Deanna Kamienski, Beth Allan, and Maureen Riordan
  
Generate a summary of this article
Listen to this article
Beta

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced January and February 2019.

Venture Funding Reg column image

3-V Biosciences Inc., which is developing drugs for cancer and nonalcoholic steatohepatitis (NASH), raised $18m through its Series E round. New investor and partner Ascletis Pharma Inc. led and was joined by Qianhai Ark (Cayman) Investment, New Enterprise Associates, and Kleiner Perkins. Purchasers committed to fund an additional $7m through a later round. The funding was announced concurrent with 3-V granting Ascletis exclusive rights to develop, manufacture, and sell its fatty acid synthase inhibitor TVB2640 (ASC40) in Greater China for NASH. Series E proceeds will support upcoming Phase II trials in the US and China of TVB2640. 

Apic Bio Inc. closed a $40m Series A round led by Morningside Venture Investments (adds a board member), which...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.